The Administrative Component is responsible for coordinating Pilot &Feasibility Projects, Scientific Core Facilities, Enrichment, and all other activities of the P30 Center. Drs. Sorscher, Kirk and the Business Officer (Ms. Diane Baer) oversee day-to-day administrative operations, and arrange for planning, evaluation, and peer review. The objective of the Administrative Core is to provide effective and integrated processes for our CF Research Base.
Specific Aims are as follows:
Specific Aim 1. To assure smooth and coordinated operation of all P30 components. This includes ongoing assessment of the most effective ways to best serve CF investigators participating in the Center.
Specific Aim 2. To carry out P30 administrative responsibilities set forth by NIH and the University of Alabama at Birmingham. This includes budgeting, monitoring, assessment and reporting requirements associated with the Center grant. In order to accomplish these objectives, the Administrative Core implements recommendations from both internal and external advisors. P30 leadership and advisory committees assure optimal use of Center resources in a fashion that promotes synergy between P30 Components and among the UAB Research Base.
During the current funding cycle, the Administrative Core has worked diligently to assure efficient operation of the NIH Center. Core leadership is experienced and strongly committed to maintaining a rigorous, collaborative, and multidisciplinary research environment. The Core has provided dedicated leadership in these areas, and is well positioned to continue in this capacity in the future.
|Serocki, Marcin; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis 21:183-202|
|Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3:|
|Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583|
|Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8|
|Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :|
|Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102|
|McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674|
|Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304|
|Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663|
|Birket, Susan E; Davis, Joy M; Fernandez, Courtney M et al. (2018) Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight 3:|
Showing the most recent 10 out of 175 publications